• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Roche Holding AG ADR

Roche Holding AG ADR

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine

    Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine

  2. 4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

    4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

  3. Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

    Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

  4. A Strict But Sensible Foreign Dividend-Stock Strategy

    Bronze-rated Vanguard International Dividend Appreciation Index screens for stocks with consistent long-term dividend growth.

  5. This International Growth Fund Screens for Quality and Hedges Currency Risk

    WisdomTree International Hedged Quality Dividend Growth emphasizes high-quality companies.

  6. Betting Responsibly on Healthcare

    These funds offer thoughtful investments in healthcare, not tactical plays.

123

©2017 Morningstar Advisor. All right reserved.